FDA Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T-Cell Lymphoma-Reference-Cited by-同舟云学术

FDA Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T-Cell Lymphoma

Published:2007-10-01 Issue:10 Volume:12 Page:1247-1252
ISSN:1083-7159
Container-title:The Oncologist
language:en
Short-container-title:

Author:

Mann Bhupinder S.¹,Johnson John R.¹,Cohen Martin H.¹,Justice Robert¹,Pazdur Richard¹

Affiliation:

1. Division of Oncology Drug Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Rockville, Maryland, USA

Abstract

Learning Objectives After completing this course, the reader will be able to: Add vorinostat to the armamentarium of drugs for CTCL.Identify the mechanism of action of vorinostat.Identify goals of therapy of CTCL.Identify active CTCL therapies.Identify CTCL response criteria. Access and take the CME test online and receive 1 AMA PRA Category 1 Credit™ at CME.TheOncologist.com

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1634/theoncologist.12-10-1247

Reference18 articles.

1. Anticancer activities of histone deacetylase inhibitors;Bolden;Nat Rev Drug Discov,2006

2. Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies;O'Connor;J Clin Oncol,2006

3. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer;Minucci;Nat Rev Cancer,2006

4. Epigenetic therapy of cancer: Past, present and future;Yoo;Nat Rev Drug Discov,2006

5. Discovery and development of SAHA as an anticancer agent;Marks;Oncogene,2007

Cited by 1120 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Circulating tumor cells: from new biological insights to clinical practice;Signal Transduction and Targeted Therapy;2024-09-02

2. Deciphering the drug delivery potential of Type1 lipid transfer protein from Citrus sinensis for enhancing the therapeutic efficacy of drugs;Biochemical and Biophysical Research Communications;2024-09

3. Advances in dual-targeting inhibitors of HDAC6 for cancer treatment;European Journal of Medicinal Chemistry;2024-09

4. Targeting the Tumor Epigenetic Regulator SETDB1 for Tumor Therapy;Current Cancer Drug Targets;2024-08-27

5. Histone deacetylase inhibitor and PD‑1 blockade synergistically inhibit B‑cell lymphoma progression in mice model by promoting T‑cell infiltration and apoptosis;Oncology Reports;2024-08-07